权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cellularly resolved molecular pathway assessment in biopsies via spectral imaging

通过光谱成像进行活检中细胞解析的分子途径评估

基本信息

批准号：
7754755
负责人：
RICHARD M. LEVENSON
金额：
$ 90.1万
依托单位：
CAMBRIDGE RESEARCH AND INSTRUMENTATION
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-28 至 2012-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7754755
关键词：
Address Affect Algorithms Animals Antibodies Antigens Archives Area Attention Automation Avastin BAY 54-9085 BIK gene Benign Biological Assay Biological Preservation Biology Biometry Biopsy British Columbia CD34 gene Calibration Cell Nucleus Cell Surface Receptors Cells Certification Classification Clinical Clinical Laboratory Information Systems Clinical Research Clinical Trials Colon Carcinoma Computer software Computers Correlative Study Coupled Data Detection Development Diagnosis Discrimination Disease Drug Industry Elements Employment Engineering Ensure Epidermal Growth Factor Receptor Epitopes Evaluation Event Excision Fixatives Fluorescence Formalin Funding Future Generations Goals Guidelines Harvest Histocompatibility Testing Hour Human Image Image Analysis Imagery Imaging technology Immunofluorescence Immunologic Immunohistochemistry Individual Industry Kidney Label Learning Length Life Light Lighting Location MEKs Machine Learning Malignant - descriptor Malignant Neoplasms Manuals Mediator of activation protein Medical Medicine Membrane Metabolic Methods Modality Modeling Molecular Molecular Target Monitor Mus Nuclear Antigens Nuclear Protein Nuclear Proteins Operative Surgical Procedures Optics Outcome PTEN gene Paraffin Embedding Pathologist Pathology Pathway interactions Patient Care Patient Focused Care Patient Selection Patients Penetration Pennsylvania Pharmaceutical Preparations Pharmacologic Substance Phase Phosphoproteins Pilot Projects Play Polymers Population Predisposition Preparation Procedures Process Proteins Proteomics Proto-Oncogene Proteins c-akt Protocols documentation Reaction Reading Reagent Receptor Activation Reporting Research Research Design Resources Risk Roche brand of trastuzumab Role Sampling Scanning Sensitivity and Specificity Shapes Side Signal Pathway Signal Transduction Signaling Protein Site Slide Source Specimen Staining method Stains Study Section System Techniques Technology Testing Thick Thyroid Gland Time Tissue Fixation Tissue Microarray Tissue Sample Tissues Toxic effect Training Transillumination Translating Tumor Tissue Ultrasonography Universities Validation Variant Vascular Endothelial Growth Factor Receptor Vascular Endothelial Growth Factor Receptor-2 Vascular Endothelial Growth Factors Weight Western Blotting Work angiogenesis base cancer cell clinical material clinical practice commercialization design drug candidate drug development flexibility follow-up image processing imaging Segmentation improved instrumentation interest lapatinib malignant breast neoplasm melanoma member method development microwave electromagnetic radiation molecular pathology mouse model nanoparticle new technology novel outcome forecast prospective protein expression protein folding research study response sample fixation statistics subcutaneous tissue culture tissue processing tissue/cell culture tool treatment response tumor validation studies

项目摘要

DESCRIPTION (provided by applicant): This is a Fast-Track application to provide reliable, cellularly resolved molecular pathway assessment in cancer biopsies to assist pharmaceutical drug development and provision of patient-specific prognosis and therapy guidance ("personalized medicine"). The organizing theme is that the appropriate unit of analysis should be the individual cell as opposed to averaged tumor extracts. To this end, novel technologies will be coupled with careful methods-development. Spectral imaging and advanced image analysis tools will permit multi-target immunohistochemical (IHC) and/or immunofluorescence (IF) detection, at the cellular and subcellular level in intact tissue sections. CRi-developed image processing and machine-learning tools provide automation and sophisticated quantitation options. Multiplexed staining protocols will yield independent, potentially stoichiometric labeling with combined IHC and IF. The sensitivity of all potential markers to variations in tissue handling will be carefully assessed; some may be robust and suitable for archival tissue studies, others will be too labile. Ultrasound-assisted fixation will be tested for its ability to preserve such labile epitopes for use in prospectively acquired tissues. Four or more pathway-related proteins will be detected in tissue sections, on a cell-by-cell basis, even if co-localized and with spectrally overlapping labels. The coordinated subcellular location of the pathway molecules will be also tracked, with simultaneous assessment of cell-surface receptors (e.g., EGFR, VEGF, Her2-neu), downstream signaling proteins and phosphoproteins (e.g., pAKT, pERK), nuclear proteins (e.g., ER, Ki67), and novel players such as protein-folding mediators (e.g. BIP1). The project will combine optimized tissue protocols, multiplexed IHC/IF reagent kits, and unique machine- learning image analysis that can be used to automate region-detection and label-quantitation. All these depend on CRi's multispectral imaging approaches for assessing multiple analytes on a cell-by-cell and cell- compartment basis in tissue sections. Our collaborators will provide small-animal tumor models for early methods development, multiplexed immunohistochemical labeling of pathway proteins in clinical cancer biopsies, access to archived and prospectively acquired tissues from pathway-targeting clinical drug trials, highly informative archival tissue microarrays, access to validated, activation-specific antibodies, ultra-fast tissue fixation, and biostatistics support. The "deliverable" will be a suite of products suitable for clinical use that can provide much-needed valid information on single-cell-based pathway status in an intact tissue context to support pharmaceutical drug development efforts and provide molecularly focused patient care. Significance and lay narrative: The ability to quantitatively evaluate multiple molecular targets and pathways on a cell-by-cell basis, in a single preparation of clinical tissue, is missing from the current toolbox of personalized medicine, which lacks good means of matching novel drugs and drug candidates to specific patients. Conventional molecular pathology methods are typically limited to a single immunohistochemical (IHC) test on a given tissue section or to expensive and time-consuming proteomics or expression-array approaches (which cannot directly report out pathway activation status in cancer cell populations and subpopulations). Multiplexed IHC (including immuno-fluorescence) combined with optimized sample handling protocols to retain pathway proteins and advanced image analysis will enable the unambiguous detection of active signaling pathways, benefiting pharmaceutical research in the selection of patients for better targeted trials and in the monitoring of response, and clinical practice for diagnosis, therapy selection, and monitoring response (i.e., theranostics).

描述（由申请人提供）：